Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments

J. A. Carrasquillo, Kenneth Krohn, P. Beaumier, R. W. McGuffin, J. P. Brown, K. E. Hellström, I. Hellström, S. M. Larson

Research output: Contribution to journalArticle

199 Citations (Scopus)

Abstract

Antibodies which are directed against human tumor-associated antigens can potentially be used as carriers of radioactivity for in vivo diagnosis (radioimmunodetection) or treatment (radioimmunotherapy) of solid tumors, including colon, hepatoma, cholangiocarcinoma, and melanoma. Murine monoclonal antibodies (MOAB), produced by the hybridoma technique of Kohler and Milstein, are replacing conventional heterosera as sources of antibodies, because MOAB can be produced in large quantities as reproducible reagents with homogeneous binding properties. We have studied human melanoma using MOAB IgG and Fab fragments that recognize the human melanoma-associated antigens p97 and 'high-molecular-weight antigen'. Both antigens are found in the membrane of melanomas at much larger concentrations than in normal adult tissues. We have performed radioimmunodetection studies with whole immunoglobulin and have detected 88% of lesions > 1.5 cm. We have used Fab fragments for radioimmunotherapy and have found that large doses of radiolabeled antibodies (up to 342 mCi) can be repetitively given to patients without excessive end-organ toxicity. Two of three patients treated with high-dose radiolabeled antimelanoma Fab showed an effect from the treatment. Although both technical and biologic problems remain, the use of radiolabeled antibodies that are directed against tumor-associated antigens hold future promise as a new therapeutic approach to solid tumors that are resistant to conventional therapy.

Original languageEnglish (US)
Pages (from-to)317-328
Number of pages12
JournalCancer Treatment Reports
Volume68
Issue number1
StatePublished - 1984
Externally publishedYes

Fingerprint

Immunoglobulin Fragments
Radioimmunodetection
Radioimmunotherapy
Melanoma
Immunoglobulin Fab Fragments
Antibodies
Monoclonal Antibodies
Neoplasm Antigens
Neoplasms
Antigens
Cholangiocarcinoma
Hybridomas
Therapeutics
Radioactivity
Immunoglobulins
Hepatocellular Carcinoma
Colon
Immunoglobulin G
Molecular Weight
Membranes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Carrasquillo, J. A., Krohn, K., Beaumier, P., McGuffin, R. W., Brown, J. P., Hellström, K. E., ... Larson, S. M. (1984). Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treatment Reports, 68(1), 317-328.

Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. / Carrasquillo, J. A.; Krohn, Kenneth; Beaumier, P.; McGuffin, R. W.; Brown, J. P.; Hellström, K. E.; Hellström, I.; Larson, S. M.

In: Cancer Treatment Reports, Vol. 68, No. 1, 1984, p. 317-328.

Research output: Contribution to journalArticle

Carrasquillo, JA, Krohn, K, Beaumier, P, McGuffin, RW, Brown, JP, Hellström, KE, Hellström, I & Larson, SM 1984, 'Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments', Cancer Treatment Reports, vol. 68, no. 1, pp. 317-328.
Carrasquillo JA, Krohn K, Beaumier P, McGuffin RW, Brown JP, Hellström KE et al. Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treatment Reports. 1984;68(1):317-328.
Carrasquillo, J. A. ; Krohn, Kenneth ; Beaumier, P. ; McGuffin, R. W. ; Brown, J. P. ; Hellström, K. E. ; Hellström, I. ; Larson, S. M. / Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. In: Cancer Treatment Reports. 1984 ; Vol. 68, No. 1. pp. 317-328.
@article{8e5bc391da75477980ee269e1aed3f81,
title = "Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments",
abstract = "Antibodies which are directed against human tumor-associated antigens can potentially be used as carriers of radioactivity for in vivo diagnosis (radioimmunodetection) or treatment (radioimmunotherapy) of solid tumors, including colon, hepatoma, cholangiocarcinoma, and melanoma. Murine monoclonal antibodies (MOAB), produced by the hybridoma technique of Kohler and Milstein, are replacing conventional heterosera as sources of antibodies, because MOAB can be produced in large quantities as reproducible reagents with homogeneous binding properties. We have studied human melanoma using MOAB IgG and Fab fragments that recognize the human melanoma-associated antigens p97 and 'high-molecular-weight antigen'. Both antigens are found in the membrane of melanomas at much larger concentrations than in normal adult tissues. We have performed radioimmunodetection studies with whole immunoglobulin and have detected 88{\%} of lesions > 1.5 cm. We have used Fab fragments for radioimmunotherapy and have found that large doses of radiolabeled antibodies (up to 342 mCi) can be repetitively given to patients without excessive end-organ toxicity. Two of three patients treated with high-dose radiolabeled antimelanoma Fab showed an effect from the treatment. Although both technical and biologic problems remain, the use of radiolabeled antibodies that are directed against tumor-associated antigens hold future promise as a new therapeutic approach to solid tumors that are resistant to conventional therapy.",
author = "Carrasquillo, {J. A.} and Kenneth Krohn and P. Beaumier and McGuffin, {R. W.} and Brown, {J. P.} and Hellstr{\"o}m, {K. E.} and I. Hellstr{\"o}m and Larson, {S. M.}",
year = "1984",
language = "English (US)",
volume = "68",
pages = "317--328",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments

AU - Carrasquillo, J. A.

AU - Krohn, Kenneth

AU - Beaumier, P.

AU - McGuffin, R. W.

AU - Brown, J. P.

AU - Hellström, K. E.

AU - Hellström, I.

AU - Larson, S. M.

PY - 1984

Y1 - 1984

N2 - Antibodies which are directed against human tumor-associated antigens can potentially be used as carriers of radioactivity for in vivo diagnosis (radioimmunodetection) or treatment (radioimmunotherapy) of solid tumors, including colon, hepatoma, cholangiocarcinoma, and melanoma. Murine monoclonal antibodies (MOAB), produced by the hybridoma technique of Kohler and Milstein, are replacing conventional heterosera as sources of antibodies, because MOAB can be produced in large quantities as reproducible reagents with homogeneous binding properties. We have studied human melanoma using MOAB IgG and Fab fragments that recognize the human melanoma-associated antigens p97 and 'high-molecular-weight antigen'. Both antigens are found in the membrane of melanomas at much larger concentrations than in normal adult tissues. We have performed radioimmunodetection studies with whole immunoglobulin and have detected 88% of lesions > 1.5 cm. We have used Fab fragments for radioimmunotherapy and have found that large doses of radiolabeled antibodies (up to 342 mCi) can be repetitively given to patients without excessive end-organ toxicity. Two of three patients treated with high-dose radiolabeled antimelanoma Fab showed an effect from the treatment. Although both technical and biologic problems remain, the use of radiolabeled antibodies that are directed against tumor-associated antigens hold future promise as a new therapeutic approach to solid tumors that are resistant to conventional therapy.

AB - Antibodies which are directed against human tumor-associated antigens can potentially be used as carriers of radioactivity for in vivo diagnosis (radioimmunodetection) or treatment (radioimmunotherapy) of solid tumors, including colon, hepatoma, cholangiocarcinoma, and melanoma. Murine monoclonal antibodies (MOAB), produced by the hybridoma technique of Kohler and Milstein, are replacing conventional heterosera as sources of antibodies, because MOAB can be produced in large quantities as reproducible reagents with homogeneous binding properties. We have studied human melanoma using MOAB IgG and Fab fragments that recognize the human melanoma-associated antigens p97 and 'high-molecular-weight antigen'. Both antigens are found in the membrane of melanomas at much larger concentrations than in normal adult tissues. We have performed radioimmunodetection studies with whole immunoglobulin and have detected 88% of lesions > 1.5 cm. We have used Fab fragments for radioimmunotherapy and have found that large doses of radiolabeled antibodies (up to 342 mCi) can be repetitively given to patients without excessive end-organ toxicity. Two of three patients treated with high-dose radiolabeled antimelanoma Fab showed an effect from the treatment. Although both technical and biologic problems remain, the use of radiolabeled antibodies that are directed against tumor-associated antigens hold future promise as a new therapeutic approach to solid tumors that are resistant to conventional therapy.

UR - http://www.scopus.com/inward/record.url?scp=0021352277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021352277&partnerID=8YFLogxK

M3 - Article

C2 - 6607111

AN - SCOPUS:0021352277

VL - 68

SP - 317

EP - 328

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -